Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S19-S25

  Versijpt, Jan ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Alzheimer's disease; cholinesterase inhibitors; economics; memantine; pharmaceutical; vascular dementia

Indexed keywords

CEREBROLYSIN; CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; COGNITION; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; ECONOMIC EVALUATION; GINKGO BILOBA; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; MEDICAL CARE; META ANALYSIS (TOPIC); MULTIINFARCT DEMENTIA; NONHUMAN; NURSING HOME; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; COST BENEFIT ANALYSIS; DEMENTIA, VASCULAR; ECONOMICS; PHARMACOECONOMICS;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DEMENTIA, VASCULAR; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 84911922370     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132639     Document Type: Conference Paper

References (59)

1. Brodaty H, Breteler MM, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg PA, Scheltens P, De SB (2011) The world of dementia beyond 2020. J Am Geriatr Soc 59, 923-927.
2. Qiu C, Kivipelto M, von SE (2009) Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11, 111-128.
3. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di CA, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, HofmanA(2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S4-S9.
4. Abbott A (2011) Dementia: A problem for our age. Nature 475, S2-S4.
5. Lowin A, Knapp M, McCrone P (2001) Alzheimer's disease in the UK: Comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry 16, 1143-1148.
6. Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JJ, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, PrinceM(2009) Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: A 10/66 Dementia Research Group population-based survey. Lancet 374, 1821-1830.
7. Wimo A, Winblad B, Jonsson L (2010) The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement 6, 98-103.
8. Wimo A, Winblad B, Jonsson L (2007) An estimate of the totalworldwide societal costs of dementia in 2005. Alzheimers Dement 3, 81-91.
9. Jonsson L, Eriksdotter JM, Kilander L, Soininen H, Hallikainen M,Waldemar G, Nygaard H, Andreasen N,Winblad B, Wimo A (2006) Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 21, 449-459.
10. Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F (2004) Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs Aging 21, 677-686.
11. Waldemar G, Phung KT, Burns A, Georges J, Hansen FR, Iliffe S, Marking C, Rikkert MO, Selmes J, Stoppe G, Sartorius N (2007) Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 22, 47-54.
12. Gustavsson A, Jonsson L, Rapp T, Reynish E, Ousset PJ, Andrieu S, Cantet C, Winblad B, Vellas B, Wimo A (2010) Differences in resource use and costs of dementia care between European countries: Baseline data from the ICTUS study. J Nutr Health Aging 14, 648-654.
13. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van OJ, Vos P, XuW, Wittchen HU, Jonsson B, Olesen J (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21, 718-779.
14. World Health Organization (2004) The global burden of disease: 2004 update.Available at: http://www.who.int/healthinfo/global burden disease/2004 report update/en/index.html [15] Ballard C, Sorensen S, Sharp S (2007) Pharmacological therapy for people with Alzheimer's disease: The balance of clinical effectiveness, ethical issues and social and healthcare costs. J Alzheimers Dis 12, 53-59.
15. OremusM(2008) Systematic reviewof economic evaluations of Alzheimer's disease medications. Expert Rev Pharmacoecon Outcomes Res 8, 273-289.
16. GreenC(2007) Modelling disease progression in Alzheimer's disease: A review of modelling methods used for costeffectiveness analysis. Pharmacoeconomics 25, 735-750.
17. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging 3, 211-225.
18. Rockwood K, Fay S, Gorman M, Carver D, Graham JE (2007) The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol 7, 26.
19. Rodda J, Carter J (2012) Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 344, e2986.
20. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P,Wailoo A, Jeffreys M, HydeC (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol Assess 16, 1-470.
21. Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, Seux ML, Forette F (2004) Donepezil for the treatment of mild to moderate Alzheimer's disease in France: The economic implications. Dement Geriatr Cogn Disord 17, 5-13.
22. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V (2004) Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63, 644-650.
23. Garfield FB, Getsios D, Caro JJ,Wimo A,Winblad B (2002) Assessment of Health Economics in Alzheimer's Disease (AHEAD): Treatment with galantamine in Sweden. Pharmacoeconomics 20, 629-637.
24. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51, 937-944.
25. Getsios D, Blume S, Ishak KJ, Maclaine GD (2010) Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: A UK evaluation using discrete-event simulation. Pharmacoeconomics 28, 411-427.
26. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA (2000) Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 17, 351-360.
27. Marin D, Amaya K, Casciano R, Puder KL, Casciano J, Chang S, Snyder EH, Cheng I, Cuccia AJ (2003) Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 15, 385-398.
28. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G (2003) Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 25, 1806-1825.
29. O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S (1999) Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 47, 570-578.
30. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R (2003) Assessment of health economics in Alzheimer's disease (AHEAD): Treatment with galantamine in the UK. Int J Geriatr Psychiatry 18, 740-747.
31. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 363, 2105-2115.
32. Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D (2004) AD2000: Design and conclusions. Lancet 364, 1213-1214.
33. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A (2005) Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 23, 1271-1282.
34. Stewart A, Phillips R, Dempsey G (1998) Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 13, 445-453.
35. Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T (2004) Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin 20, 1221-1225.
36. Hill J, Fillit H, Thomas SK, Chang S (2006) Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics 24, 265-280.
37. Small GW, McDonnell DD, Brooks RL, Papadopoulos G (2002) The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc 50, 321-327.
38. Weimer DL, Sager MA (2009) Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes. Alzheimers Dement 5, 215-226.
39. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
40. Schneider LS, Dagerman KS, Higgins JP, McShane R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68, 991-998.
41. Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M (2012) Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. Int J Geriatr Psychiatry 27, 573-582.
42. Lopez OL, Becker JT,Wahed AS, Saxton J, Sweet RA,Wolk DA, Klunk W, Dekosky ST (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80, 600-607.
43. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324.
44. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366, 893-903.
45. Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G (2007) Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 23, 1187-1197.
46. Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S (2013) The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: Costeffectiveness analysis in France. Eur J Health Econ. doi: 10.1007/s10198-013-0523-y [Epub ahead of print]
47. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 13, 43-54.
48. Bae CY, Cho CY, Cho K, Hoon OB, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, LeeH(2000)Adoubleblind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 48, 1566-1571.
49. Panisset M, Gauthier S, Moessler H,WindischM(2002) Cerebrolysin in Alzheimer's disease:Arandomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 109, 1089-1104.
50. Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, Ritter R, Schmidt R, Taneri Z,WintererW,Koper D, Kasper S, Rainer M, Moessler H (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 16, 253-263.
51. Alvarez XA, Cacabelos R, Sampedro C, CouceiroV, Aleixandre M, Vargas M, Linares C, Granizo E, Garcia-Fantini M, Baurecht W, Doppler E, Moessler H (2011) Combination treatment in Alzheimer's disease: Results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res 8, 583-591.
52. Ihl R (2012) Gingko biloba extract EGb 761(R): Clinical data in dementia. Int Psychogeriatr 24(Suppl 1), S35-S40.
53. Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia:Ameta-analysis of randomised controlled trials. Lancet Neurol 6, 782-792.
54. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american heart association/american stroke association. Stroke 42, 2672-2713.
55. Guekht AB, Moessler H, Novak PH, Gusev EI (2011) Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 20, 310-318.
56. Plosker GL, Gauthier S (2009) Cerebrolysin: A review of its use in dementia. Drugs Aging 26, 893-915.
57. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L (2013) Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 1, CD008900.
58. Baskys A, Cheng JX (2012) Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives. Exp Gerontol 47, 887-891.
59. Larson EB, Yaffe K, Langa KM (2013) New insights into the dementia epidemic. N Engl J Med 369, 2275-2277.